Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics.
Identifieur interne : 000994 ( Main/Exploration ); précédent : 000993; suivant : 000995Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics.
Auteurs : David Gurwitz [Israël]Source :
- Drug development research [ 1098-2299 ] ; 2020.
Abstract
At the time of writing this commentary (February 2020), the coronavirus COVID-19 epidemic has already resulted in more fatalities compared with the SARS and MERS coronavirus epidemics combined. Therapeutics that may assist to contain its rapid spread and reduce its high mortality rates are urgently needed. Developing vaccines against the SARS-CoV-2 virus may take many months. Moreover, vaccines based on viral-encoded peptides may not be effective against future coronavirus epidemics, as virus mutations could make them futile. Indeed, new Influenza virus strains emerge every year, requiring new immunizations. A tentative suggestion based on existing therapeutics, which would likely be resistant to new coronavirus mutations, is to use available angiotensin receptor 1 (AT1R) blockers, such as losartan, as therapeutics for reducing the aggressiveness and mortality from SARS-CoV-2 virus infections. This idea is based on observations that the angiotensin-converting enzyme 2 (ACE2) very likely serves as the binding site for SARS-CoV-2, the strain implicated in the current COVID-19 epidemic, similarly to strain SARS-CoV implicated in the 2002-2003 SARS epidemic. This commentary elaborates on the idea of considering AT1R blockers as tentative treatment for SARS-CoV-2 infections, and proposes a research direction based on datamining of clinical patient records for assessing its feasibility.
DOI: 10.1002/ddr.21656
PubMed: 32129518
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000701
- to stream PubMed, to step Curation: 000701
- to stream PubMed, to step Checkpoint: 000787
- to stream Ncbi, to step Merge: 003287
- to stream Ncbi, to step Curation: 003287
- to stream Ncbi, to step Checkpoint: 003287
- to stream Main, to step Merge: 000994
- to stream Main, to step Curation: 000994
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics.</title><author><name sortKey="Gurwitz, David" sort="Gurwitz, David" uniqKey="Gurwitz D" first="David" last="Gurwitz">David Gurwitz</name><affiliation wicri:level="1"><nlm:affiliation>Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.</nlm:affiliation><country xml:lang="fr">Israël</country><wicri:regionArea>Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv</wicri:regionArea><wicri:noRegion>Tel-Aviv</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32129518</idno><idno type="pmid">32129518</idno><idno type="doi">10.1002/ddr.21656</idno><idno type="wicri:Area/PubMed/Corpus">000701</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000701</idno><idno type="wicri:Area/PubMed/Curation">000701</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000701</idno><idno type="wicri:Area/PubMed/Checkpoint">000787</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000787</idno><idno type="wicri:Area/Ncbi/Merge">003287</idno><idno type="wicri:Area/Ncbi/Curation">003287</idno><idno type="wicri:Area/Ncbi/Checkpoint">003287</idno><idno type="wicri:Area/Main/Merge">000994</idno><idno type="wicri:Area/Main/Curation">000994</idno><idno type="wicri:Area/Main/Exploration">000994</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics.</title><author><name sortKey="Gurwitz, David" sort="Gurwitz, David" uniqKey="Gurwitz D" first="David" last="Gurwitz">David Gurwitz</name><affiliation wicri:level="1"><nlm:affiliation>Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.</nlm:affiliation><country xml:lang="fr">Israël</country><wicri:regionArea>Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv</wicri:regionArea><wicri:noRegion>Tel-Aviv</wicri:noRegion></affiliation></author></analytic><series><title level="j">Drug development research</title><idno type="eISSN">1098-2299</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">At the time of writing this commentary (February 2020), the coronavirus COVID-19 epidemic has already resulted in more fatalities compared with the SARS and MERS coronavirus epidemics combined. Therapeutics that may assist to contain its rapid spread and reduce its high mortality rates are urgently needed. Developing vaccines against the SARS-CoV-2 virus may take many months. Moreover, vaccines based on viral-encoded peptides may not be effective against future coronavirus epidemics, as virus mutations could make them futile. Indeed, new Influenza virus strains emerge every year, requiring new immunizations. A tentative suggestion based on existing therapeutics, which would likely be resistant to new coronavirus mutations, is to use available angiotensin receptor 1 (AT1R) blockers, such as losartan, as therapeutics for reducing the aggressiveness and mortality from SARS-CoV-2 virus infections. This idea is based on observations that the angiotensin-converting enzyme 2 (ACE2) very likely serves as the binding site for SARS-CoV-2, the strain implicated in the current COVID-19 epidemic, similarly to strain SARS-CoV implicated in the 2002-2003 SARS epidemic. This commentary elaborates on the idea of considering AT1R blockers as tentative treatment for SARS-CoV-2 infections, and proposes a research direction based on datamining of clinical patient records for assessing its feasibility.</div></front></TEI><affiliations><list><country><li>Israël</li></country></list><tree><country name="Israël"><noRegion><name sortKey="Gurwitz, David" sort="Gurwitz, David" uniqKey="Gurwitz D" first="David" last="Gurwitz">David Gurwitz</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000994 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000994 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32129518
|texte= Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32129518" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |